← boardnext 2026-08next 2027-11
MPLT
MapLight Therapeuticsdistress 2/10 · well-funded / low risk$35.40+0%today-11% from 52w high
Psychiatry / CNS 1
Lead: schizophrenia · target Muscarinic · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$395M
Runway
2.7 yrs
Shares 1y
-6%
Price & events
+90.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-4.9%
1W
+23.6%
1M
+21.6%
3M
+96.9%
6M
—
1Y
—
2Y
—
5Y
+93.0%
All
Overview
- Market Cap
- $1.50B
- Volume
- 9.54K
- 52 Week Range
- $12.81 – $39.80
- Total Shares
- 42.44M
- Float Shares
- 13.32M
- Short %
- 11.72%
- % Held by Insiders
- 51.16%
- % Held by Institutions
- 56.01%
- RVOL
- 0.02x
Pipeline stages · 2 programs
ML-007C-MA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ML-004 (IR)/(ER) tablet
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 final ~2027-02-28 | Phase 2 | ML-007C-MA BID, ML-007C-MA QDfast track | Schizophrenia | 307 | active not recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | ML-004 (IR)/(ER) tablet | Autism Spectrum Disorder | — | enrolling by invitation |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | ML-007C-MAfast track | Psychosis Associated With Alzheimer's Disease | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-04-15 | Phase 2 | ML-007C-MAfast track | Psychosis Associated With Alzheimer's Disease | — | recruiting |
| 2030-02 Estimated 50% readout ~2030-03-18 | Phase 2 | ML-007C-MAfast track | Schizophrenia | — | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03-10 | Phase 2 | ML-004 (IR)/(ER) tablet, ML-004 Placebo | Autism Spectrum Disorder | 168 | completed |
Upcoming readouts & decisions · our signals
2 upcoming events have our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 8
- second half of 2027Guided 55%readoutPhase 2ML-007C-MA · Topline results from Phase 2 VISTA trialSEC 8-K
- second half of 2026Guided 55%readoutPhase 2ML-004 · Topline results from Phase 2 IRIS trialSEC 8-K
- second half of 2026Guided 55%readoutPhase 2ML-007C-MA · Topline results from Phase 2 ZEPHYR trialSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryML-021 · Complete IND-enabling studies for ML-021SEC 8-K
- third quarter of 2026Guided 70%readoutPhase 2ML-007C-MA · Topline results from Phase 2 ZEPHYR trialSEC 8-K
- Q3 2026Guided 70%readoutPhase 2ML-004 · Topline results from Phase 2 VISTA trialSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- April 2026enrollment completesecondaryPhase 2ML-007C-MA · Expected to reach target enrollment of ~300 participants in ZEPHYR trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+17% upside) · 12 analysts
- 2026-07-21BMO CapitalOutperform
- 2026-07-21UBSBuy
- 2026-07-10NeedhamBuy
- 2026-06-25Raymond JamesStrong Buy
- 2026-06-23Craig-HallumBuy
- 2026-06-22NeedhamBuy
Competitors — Muscarinic
- none identified
Recent news
- 2026-07-21Form 4 MapLight Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says - marketscreener.com
- 2026-07-21UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating - Moomoo
- 2026-07-21MPLT Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
- 2026-07-21UBS raises MapLight Therapeutics stock price target on trial data - Investing.com
- 2026-07-21MapLight Therapeutics general counsel sells $607,870 in shares By Investing.com - Investing.com South Africa
- 2026-07-21MapLight Therapeutics CSO James Woodruff sells $673k in shares for tax - Investing.com
- 2026-07-21MapLight Therapeutics CEO Kroeger sells $5.4m in company stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.